## **Steve Kopko**

From: Dana Booth

Sent: Wednesday, December 8, 2021 6:29 PM

To: COADataStandards

Cc: Sviglin, Helena; Wagschal, Yaffa; Wilson, Stephen E; Steve Kopko; Diane Corey

**Subject:** ADSD and ANSD request for FDA 3rd review

Attachments: CDISC QRS 3rd Review Request ANSD V1.0 2021-12-08.docx; CDISC QRS 3rd Review

Request ADSD V1.0 2021-12-08.docx; ADSD changes since 2021-05-24 version.docx; ANSD changes since 2021-05-24 version.docx; SDTM QS-ADSD V1.0 Approved.docx; SDTM QS-ANSD V1.0 Approved.docx; ANSD Annotated CRF.pdf; ADSD Annotated

CRF.pdf; PROC\_ADSD\_ANSD\_UserManuaReleasedV1\_20190330.pdf

Dear Helena et al,

Attached please review requests for the FDA to please perform a  $3^{rd}$  review of the QRS Supplements for ADSD v1.0 and ANSD v1.0. In addition, please find attached:

- PROC\_ADSD\_ANSD\_UserManuaReleasedV1\_20190330.PDF.: The Critical Path Institute owns the copyright for the ADSD V1.0 and ANSD v1.0 instruments. They have provided the user manual for this FDA review only.
- SDTM QS-ANSD V1.0 Approved Word Supplement, dated 21-12-08.
- ANSD changes since the 2021-05-24 version: This is a Word comparison of the document we included with the 2<sup>nd</sup> review and the Word document included in this review and shows all changes since the 2021-05-24 version.
- The annotated CRF for the ANSD V1.0, which did not change.

•

- SDTM QS-ADSD V1.0 Approved Word Supplement, dated 21-12-08.
- ADSD changes since the 2021-05-24 version: This is a Word comparison of the document we included with the 2<sup>nd</sup> review and the Word document included in this review and shows all changes since the 2021-05-24 version.
- The annotated CRF for the ADSD V1.0, which did not change.

Please let us know if you have any questions.

Thank you!

## **Dana Booth**



Project Manager, Foundational Standards | QRS Co-lead

Office 1.512.363.5826 | Mobile +1.503.551.5362









